COVID-19 Impact on Global Mucopolysaccharidosis (MPS) Treatment Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-mucopolysaccharidosis-mps-treatment-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global Mucopolysaccharidosis (MPS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Mucopolysaccharidosis (MPS) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Sanofi
- Shire (Takeda)
- BioMarin Pharmaceutical
- Esteve
- REGENXBIO Inc
- Sangamo Therapeutics
- Ultragenyx Pharmaceutical
- Abeona Therapeutics
- ArmaGen
- Eloxx Pharmaceuticals
- Inventiva
- Stem Cell Therapies
- Enzyme Replacement Therapies
- Hospitals
- Clinics
- Homecare
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Mucopolysaccharidosis (MPS) Treatment status, future forecast, growth opportunity, key market and key players.
- To present the Mucopolysaccharidosis (MPS) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Mucopolysaccharidosis (MPS) Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Stem Cell Therapies
1.4.3 Enzyme Replacement Therapies
1.5 Market by Application
1.5.1 Global Mucopolysaccharidosis (MPS) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Homecare
1.6 Coronavirus Disease 2019 (Covid-19): Mucopolysaccharidosis (MPS) Treatment Industry Impact
1.6.1 How the Covid-19 is Affecting the Mucopolysaccharidosis (MPS) Treatment Industry
1.6.1.1 Mucopolysaccharidosis (MPS) Treatment Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Mucopolysaccharidosis (MPS) Treatment Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Mucopolysaccharidosis (MPS) Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Mucopolysaccharidosis (MPS) Treatment Market Perspective (2015-2026)
2.2 Mucopolysaccharidosis (MPS) Treatment Growth Trends by Regions
2.2.1 Mucopolysaccharidosis (MPS) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Mucopolysaccharidosis (MPS) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Mucopolysaccharidosis (MPS) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Mucopolysaccharidosis (MPS) Treatment Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Mucopolysaccharidosis (MPS) Treatment Players by Market Size
3.1.1 Global Top Mucopolysaccharidosis (MPS) Treatment Players by Revenue (2015-2020)
3.1.2 Global Mucopolysaccharidosis (MPS) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Mucopolysaccharidosis (MPS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Mucopolysaccharidosis (MPS) Treatment Market Concentration Ratio
3.2.1 Global Mucopolysaccharidosis (MPS) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis (MPS) Treatment Revenue in 2019
3.3 Mucopolysaccharidosis (MPS) Treatment Key Players Head office and Area Served
3.4 Key Players Mucopolysaccharidosis (MPS) Treatment Product Solution and Service
3.5 Date of Enter into Mucopolysaccharidosis (MPS) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Mucopolysaccharidosis (MPS) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Type (2021-2026)
5 MUCOPOLYSACCHARIDOSIS (MPS) TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
5.2 Global Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
6.2 Mucopolysaccharidosis (MPS) Treatment Key Players in North America (2019-2020)
6.3 North America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
6.4 North America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
7.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Europe (2019-2020)
7.3 Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
7.4 Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
8 CHINA
8.1 China Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
8.2 Mucopolysaccharidosis (MPS) Treatment Key Players in China (2019-2020)
8.3 China Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
8.4 China Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
9.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Japan (2019-2020)
9.3 Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
9.4 Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
10.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
11 INDIA
11.1 India Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
11.2 Mucopolysaccharidosis (MPS) Treatment Key Players in India (2019-2020)
11.3 India Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
11.4 India Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
12.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Sanofi
13.1.1 Sanofi Company Details
13.1.2 Sanofi Business Overview and Its Total Revenue
13.1.3 Sanofi Mucopolysaccharidosis (MPS) Treatment Introduction
13.1.4 Sanofi Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020))
13.1.5 Sanofi Recent Development
13.2 Shire (Takeda)
13.2.1 Shire (Takeda) Company Details
13.2.2 Shire (Takeda) Business Overview and Its Total Revenue
13.2.3 Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Introduction
13.2.4 Shire (Takeda) Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.2.5 Shire (Takeda) Recent Development
13.3 BioMarin Pharmaceutical
13.3.1 BioMarin Pharmaceutical Company Details
13.3.2 BioMarin Pharmaceutical Business Overview and Its Total Revenue
13.3.3 BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Introduction
13.3.4 BioMarin Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.3.5 BioMarin Pharmaceutical Recent Development
13.4 Esteve
13.4.1 Esteve Company Details
13.4.2 Esteve Business Overview and Its Total Revenue
13.4.3 Esteve Mucopolysaccharidosis (MPS) Treatment Introduction
13.4.4 Esteve Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.4.5 Esteve Recent Development
13.5 REGENXBIO Inc
13.5.1 REGENXBIO Inc Company Details
13.5.2 REGENXBIO Inc Business Overview and Its Total Revenue
13.5.3 REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Introduction
13.5.4 REGENXBIO Inc Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.5.5 REGENXBIO Inc Recent Development
13.6 Sangamo Therapeutics
13.6.1 Sangamo Therapeutics Company Details
13.6.2 Sangamo Therapeutics Business Overview and Its Total Revenue
13.6.3 Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Introduction
13.6.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.6.5 Sangamo Therapeutics Recent Development
13.7 Ultragenyx Pharmaceutical
13.7.1 Ultragenyx Pharmaceutical Company Details
13.7.2 Ultragenyx Pharmaceutical Business Overview and Its Total Revenue
13.7.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Introduction
13.7.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.7.5 Ultragenyx Pharmaceutical Recent Development
13.8 Abeona Therapeutics
13.8.1 Abeona Therapeutics Company Details
13.8.2 Abeona Therapeutics Business Overview and Its Total Revenue
13.8.3 Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Introduction
13.8.4 Abeona Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.8.5 Abeona Therapeutics Recent Development
13.9 ArmaGen
13.9.1 ArmaGen Company Details
13.9.2 ArmaGen Business Overview and Its Total Revenue
13.9.3 ArmaGen Mucopolysaccharidosis (MPS) Treatment Introduction
13.9.4 ArmaGen Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.9.5 ArmaGen Recent Development
13.10 Eloxx Pharmaceuticals
13.10.1 Eloxx Pharmaceuticals Company Details
13.10.2 Eloxx Pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Introduction
13.10.4 Eloxx Pharmaceuticals Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.10.5 Eloxx Pharmaceuticals Recent Development
13.11 Inventiva
10.11.1 Inventiva Company Details
10.11.2 Inventiva Business Overview and Its Total Revenue
10.11.3 Inventiva Mucopolysaccharidosis (MPS) Treatment Introduction
10.11.4 Inventiva Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
10.11.5 Inventiva Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Mucopolysaccharidosis (MPS) Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Stem Cell Therapies
1.4.3 Enzyme Replacement Therapies
1.5 Market by Application
1.5.1 Global Mucopolysaccharidosis (MPS) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Homecare
1.6 Coronavirus Disease 2019 (Covid-19): Mucopolysaccharidosis (MPS) Treatment Industry Impact
1.6.1 How the Covid-19 is Affecting the Mucopolysaccharidosis (MPS) Treatment Industry
1.6.1.1 Mucopolysaccharidosis (MPS) Treatment Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Mucopolysaccharidosis (MPS) Treatment Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Mucopolysaccharidosis (MPS) Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Mucopolysaccharidosis (MPS) Treatment Market Perspective (2015-2026)
2.2 Mucopolysaccharidosis (MPS) Treatment Growth Trends by Regions
2.2.1 Mucopolysaccharidosis (MPS) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Mucopolysaccharidosis (MPS) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Mucopolysaccharidosis (MPS) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Mucopolysaccharidosis (MPS) Treatment Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Mucopolysaccharidosis (MPS) Treatment Players by Market Size
3.1.1 Global Top Mucopolysaccharidosis (MPS) Treatment Players by Revenue (2015-2020)
3.1.2 Global Mucopolysaccharidosis (MPS) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Mucopolysaccharidosis (MPS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Mucopolysaccharidosis (MPS) Treatment Market Concentration Ratio
3.2.1 Global Mucopolysaccharidosis (MPS) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis (MPS) Treatment Revenue in 2019
3.3 Mucopolysaccharidosis (MPS) Treatment Key Players Head office and Area Served
3.4 Key Players Mucopolysaccharidosis (MPS) Treatment Product Solution and Service
3.5 Date of Enter into Mucopolysaccharidosis (MPS) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Mucopolysaccharidosis (MPS) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Type (2021-2026)
5 MUCOPOLYSACCHARIDOSIS (MPS) TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
5.2 Global Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
6.2 Mucopolysaccharidosis (MPS) Treatment Key Players in North America (2019-2020)
6.3 North America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
6.4 North America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
7.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Europe (2019-2020)
7.3 Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
7.4 Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
8 CHINA
8.1 China Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
8.2 Mucopolysaccharidosis (MPS) Treatment Key Players in China (2019-2020)
8.3 China Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
8.4 China Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
9.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Japan (2019-2020)
9.3 Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
9.4 Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
10.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
11 INDIA
11.1 India Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
11.2 Mucopolysaccharidosis (MPS) Treatment Key Players in India (2019-2020)
11.3 India Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
11.4 India Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size (2015-2020)
12.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Sanofi
13.1.1 Sanofi Company Details
13.1.2 Sanofi Business Overview and Its Total Revenue
13.1.3 Sanofi Mucopolysaccharidosis (MPS) Treatment Introduction
13.1.4 Sanofi Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020))
13.1.5 Sanofi Recent Development
13.2 Shire (Takeda)
13.2.1 Shire (Takeda) Company Details
13.2.2 Shire (Takeda) Business Overview and Its Total Revenue
13.2.3 Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Introduction
13.2.4 Shire (Takeda) Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.2.5 Shire (Takeda) Recent Development
13.3 BioMarin Pharmaceutical
13.3.1 BioMarin Pharmaceutical Company Details
13.3.2 BioMarin Pharmaceutical Business Overview and Its Total Revenue
13.3.3 BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Introduction
13.3.4 BioMarin Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.3.5 BioMarin Pharmaceutical Recent Development
13.4 Esteve
13.4.1 Esteve Company Details
13.4.2 Esteve Business Overview and Its Total Revenue
13.4.3 Esteve Mucopolysaccharidosis (MPS) Treatment Introduction
13.4.4 Esteve Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.4.5 Esteve Recent Development
13.5 REGENXBIO Inc
13.5.1 REGENXBIO Inc Company Details
13.5.2 REGENXBIO Inc Business Overview and Its Total Revenue
13.5.3 REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Introduction
13.5.4 REGENXBIO Inc Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.5.5 REGENXBIO Inc Recent Development
13.6 Sangamo Therapeutics
13.6.1 Sangamo Therapeutics Company Details
13.6.2 Sangamo Therapeutics Business Overview and Its Total Revenue
13.6.3 Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Introduction
13.6.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.6.5 Sangamo Therapeutics Recent Development
13.7 Ultragenyx Pharmaceutical
13.7.1 Ultragenyx Pharmaceutical Company Details
13.7.2 Ultragenyx Pharmaceutical Business Overview and Its Total Revenue
13.7.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Introduction
13.7.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.7.5 Ultragenyx Pharmaceutical Recent Development
13.8 Abeona Therapeutics
13.8.1 Abeona Therapeutics Company Details
13.8.2 Abeona Therapeutics Business Overview and Its Total Revenue
13.8.3 Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Introduction
13.8.4 Abeona Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.8.5 Abeona Therapeutics Recent Development
13.9 ArmaGen
13.9.1 ArmaGen Company Details
13.9.2 ArmaGen Business Overview and Its Total Revenue
13.9.3 ArmaGen Mucopolysaccharidosis (MPS) Treatment Introduction
13.9.4 ArmaGen Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.9.5 ArmaGen Recent Development
13.10 Eloxx Pharmaceuticals
13.10.1 Eloxx Pharmaceuticals Company Details
13.10.2 Eloxx Pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Introduction
13.10.4 Eloxx Pharmaceuticals Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
13.10.5 Eloxx Pharmaceuticals Recent Development
13.11 Inventiva
10.11.1 Inventiva Company Details
10.11.2 Inventiva Business Overview and Its Total Revenue
10.11.3 Inventiva Mucopolysaccharidosis (MPS) Treatment Introduction
10.11.4 Inventiva Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
10.11.5 Inventiva Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Mucopolysaccharidosis (MPS) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Mucopolysaccharidosis (MPS) Treatment Revenue
Table 3. Ranking of Global Top Mucopolysaccharidosis (MPS) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Stem Cell Therapies
Table 6. Key Players of Enzyme Replacement Therapies
Table 7. COVID-19 Impact Global Market: (Four Mucopolysaccharidosis (MPS) Treatment Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Mucopolysaccharidosis (MPS) Treatment Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Mucopolysaccharidosis (MPS) Treatment Players to Combat Covid-19 Impact
Table 12. Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2015-2020)
Table 16. Global Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Mucopolysaccharidosis (MPS) Treatment Market Growth Strategy
Table 22. Main Points Interviewed from Key Mucopolysaccharidosis (MPS) Treatment Players
Table 23. Global Mucopolysaccharidosis (MPS) Treatment Revenue by Players (2015-2020) (Million US$)
Table 24. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Players (2015-2020)
Table 25. Global Top Mucopolysaccharidosis (MPS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mucopolysaccharidosis (MPS) Treatment as of 2019)
Table 26. Global Mucopolysaccharidosis (MPS) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Mucopolysaccharidosis (MPS) Treatment Product Solution and Service
Table 29. Date of Enter into Mucopolysaccharidosis (MPS) Treatment Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 32. Global Mucopolysaccharidosis (MPS) Treatment Market Size Share by Type (2015-2020)
Table 33. Global Mucopolysaccharidosis (MPS) Treatment Revenue Market Share by Type (2021-2026)
Table 34. Global Mucopolysaccharidosis (MPS) Treatment Market Size Share by Application (2015-2020)
Table 35. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 36. Global Mucopolysaccharidosis (MPS) Treatment Market Size Share by Application (2021-2026)
Table 37. North America Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 39. North America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 40. North America Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 41. North America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 42. North America Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 43. Europe Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 45. Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 47. Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 49. China Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 50. China Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 51. China Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 52. China Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 53. China Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 54. China Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 55. Japan Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 57. Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 59. Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 63. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 65. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 67. India Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 68. India Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 69. India Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 70. India Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 71. India Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 72. India Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 75. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 77. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 79. Sanofi Company Details
Table 80. Sanofi Business Overview
Table 81. Sanofi Product
Table 82. Sanofi Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 83. Sanofi Recent Development
Table 84. Shire (Takeda) Company Details
Table 85. Shire (Takeda) Business Overview
Table 86. Shire (Takeda) Product
Table 87. Shire (Takeda) Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 88. Shire (Takeda) Recent Development
Table 89. BioMarin Pharmaceutical Company Details
Table 90. BioMarin Pharmaceutical Business Overview
Table 91. BioMarin Pharmaceutical Product
Table 92. BioMarin Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 93. BioMarin Pharmaceutical Recent Development
Table 94. Esteve Company Details
Table 95. Esteve Business Overview
Table 96. Esteve Product
Table 97. Esteve Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 98. Esteve Recent Development
Table 99. REGENXBIO Inc Company Details
Table 100. REGENXBIO Inc Business Overview
Table 101. REGENXBIO Inc Product
Table 102. REGENXBIO Inc Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 103. REGENXBIO Inc Recent Development
Table 104. Sangamo Therapeutics Company Details
Table 105. Sangamo Therapeutics Business Overview
Table 106. Sangamo Therapeutics Product
Table 107. Sangamo Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 108. Sangamo Therapeutics Recent Development
Table 109. Ultragenyx Pharmaceutical Company Details
Table 110. Ultragenyx Pharmaceutical Business Overview
Table 111. Ultragenyx Pharmaceutical Product
Table 112. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 113. Ultragenyx Pharmaceutical Recent Development
Table 114. Abeona Therapeutics Business Overview
Table 115. Abeona Therapeutics Product
Table 116. Abeona Therapeutics Company Details
Table 117. Abeona Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 118. Abeona Therapeutics Recent Development
Table 119. ArmaGen Company Details
Table 120. ArmaGen Business Overview
Table 121. ArmaGen Product
Table 122. ArmaGen Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 123. ArmaGen Recent Development
Table 124. Eloxx Pharmaceuticals Company Details
Table 125. Eloxx Pharmaceuticals Business Overview
Table 126. Eloxx Pharmaceuticals Product
Table 127. Eloxx Pharmaceuticals Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 128. Eloxx Pharmaceuticals Recent Development
Table 129. Inventiva Company Details
Table 130. Inventiva Business Overview
Table 131. Inventiva Product
Table 132. Inventiva Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 133. Inventiva Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
Table 1. Mucopolysaccharidosis (MPS) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Mucopolysaccharidosis (MPS) Treatment Revenue
Table 3. Ranking of Global Top Mucopolysaccharidosis (MPS) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Stem Cell Therapies
Table 6. Key Players of Enzyme Replacement Therapies
Table 7. COVID-19 Impact Global Market: (Four Mucopolysaccharidosis (MPS) Treatment Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Mucopolysaccharidosis (MPS) Treatment Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Mucopolysaccharidosis (MPS) Treatment Players to Combat Covid-19 Impact
Table 12. Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2015-2020)
Table 16. Global Mucopolysaccharidosis (MPS) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Mucopolysaccharidosis (MPS) Treatment Market Growth Strategy
Table 22. Main Points Interviewed from Key Mucopolysaccharidosis (MPS) Treatment Players
Table 23. Global Mucopolysaccharidosis (MPS) Treatment Revenue by Players (2015-2020) (Million US$)
Table 24. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Players (2015-2020)
Table 25. Global Top Mucopolysaccharidosis (MPS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mucopolysaccharidosis (MPS) Treatment as of 2019)
Table 26. Global Mucopolysaccharidosis (MPS) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Mucopolysaccharidosis (MPS) Treatment Product Solution and Service
Table 29. Date of Enter into Mucopolysaccharidosis (MPS) Treatment Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 32. Global Mucopolysaccharidosis (MPS) Treatment Market Size Share by Type (2015-2020)
Table 33. Global Mucopolysaccharidosis (MPS) Treatment Revenue Market Share by Type (2021-2026)
Table 34. Global Mucopolysaccharidosis (MPS) Treatment Market Size Share by Application (2015-2020)
Table 35. Global Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 36. Global Mucopolysaccharidosis (MPS) Treatment Market Size Share by Application (2021-2026)
Table 37. North America Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 39. North America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 40. North America Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 41. North America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 42. North America Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 43. Europe Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 45. Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 47. Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 49. China Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 50. China Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 51. China Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 52. China Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 53. China Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 54. China Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 55. Japan Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 57. Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 59. Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 63. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 65. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 67. India Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 68. India Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 69. India Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 70. India Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 71. India Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 72. India Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Mucopolysaccharidosis (MPS) Treatment Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Mucopolysaccharidosis (MPS) Treatment Market Share (2019-2020)
Table 75. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Share by Type (2015-2020)
Table 77. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2015-2020)
Table 79. Sanofi Company Details
Table 80. Sanofi Business Overview
Table 81. Sanofi Product
Table 82. Sanofi Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 83. Sanofi Recent Development
Table 84. Shire (Takeda) Company Details
Table 85. Shire (Takeda) Business Overview
Table 86. Shire (Takeda) Product
Table 87. Shire (Takeda) Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 88. Shire (Takeda) Recent Development
Table 89. BioMarin Pharmaceutical Company Details
Table 90. BioMarin Pharmaceutical Business Overview
Table 91. BioMarin Pharmaceutical Product
Table 92. BioMarin Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 93. BioMarin Pharmaceutical Recent Development
Table 94. Esteve Company Details
Table 95. Esteve Business Overview
Table 96. Esteve Product
Table 97. Esteve Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 98. Esteve Recent Development
Table 99. REGENXBIO Inc Company Details
Table 100. REGENXBIO Inc Business Overview
Table 101. REGENXBIO Inc Product
Table 102. REGENXBIO Inc Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 103. REGENXBIO Inc Recent Development
Table 104. Sangamo Therapeutics Company Details
Table 105. Sangamo Therapeutics Business Overview
Table 106. Sangamo Therapeutics Product
Table 107. Sangamo Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 108. Sangamo Therapeutics Recent Development
Table 109. Ultragenyx Pharmaceutical Company Details
Table 110. Ultragenyx Pharmaceutical Business Overview
Table 111. Ultragenyx Pharmaceutical Product
Table 112. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 113. Ultragenyx Pharmaceutical Recent Development
Table 114. Abeona Therapeutics Business Overview
Table 115. Abeona Therapeutics Product
Table 116. Abeona Therapeutics Company Details
Table 117. Abeona Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 118. Abeona Therapeutics Recent Development
Table 119. ArmaGen Company Details
Table 120. ArmaGen Business Overview
Table 121. ArmaGen Product
Table 122. ArmaGen Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 123. ArmaGen Recent Development
Table 124. Eloxx Pharmaceuticals Company Details
Table 125. Eloxx Pharmaceuticals Business Overview
Table 126. Eloxx Pharmaceuticals Product
Table 127. Eloxx Pharmaceuticals Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 128. Eloxx Pharmaceuticals Recent Development
Table 129. Inventiva Company Details
Table 130. Inventiva Business Overview
Table 131. Inventiva Product
Table 132. Inventiva Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020) (Million US$)
Table 133. Inventiva Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Stem Cell Therapies Features
Figure 3. Enzyme Replacement Therapies Features
Figure 4. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Homecare Case Studies
Figure 8. Mucopolysaccharidosis (MPS) Treatment Report Years Considered
Figure 9. Global Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions: 2020 VS 2026
Figure 11. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Players in 2019
Figure 14. Global Top Mucopolysaccharidosis (MPS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mucopolysaccharidosis (MPS) Treatment as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis (MPS) Treatment Revenue in 2019
Figure 16. North America Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Sanofi Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 25. Shire (Takeda) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Shire (Takeda) Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 27. BioMarin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. BioMarin Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 29. Esteve Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Esteve Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 31. REGENXBIO Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. REGENXBIO Inc Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 33. Sangamo Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 35. Ultragenyx Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 37. Abeona Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Abeona Therapeutics Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 39. ArmaGen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 41. Eloxx Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Eloxx Pharmaceuticals Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 43. Inventiva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Inventiva Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 45. Bottom-up and Top-down Approaches for This Report
Figure 46. Data Triangulation
Figure 47. Key Executives Interviewed
Figure 1. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Stem Cell Therapies Features
Figure 3. Enzyme Replacement Therapies Features
Figure 4. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Homecare Case Studies
Figure 8. Mucopolysaccharidosis (MPS) Treatment Report Years Considered
Figure 9. Global Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions: 2020 VS 2026
Figure 11. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Mucopolysaccharidosis (MPS) Treatment Market Share by Players in 2019
Figure 14. Global Top Mucopolysaccharidosis (MPS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mucopolysaccharidosis (MPS) Treatment as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis (MPS) Treatment Revenue in 2019
Figure 16. North America Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Sanofi Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 25. Shire (Takeda) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Shire (Takeda) Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 27. BioMarin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. BioMarin Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 29. Esteve Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Esteve Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 31. REGENXBIO Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. REGENXBIO Inc Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 33. Sangamo Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 35. Ultragenyx Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 37. Abeona Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Abeona Therapeutics Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 39. ArmaGen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 41. Eloxx Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Eloxx Pharmaceuticals Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 43. Inventiva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Inventiva Revenue Growth Rate in Mucopolysaccharidosis (MPS) Treatment Business (2015-2020)
Figure 45. Bottom-up and Top-down Approaches for This Report
Figure 46. Data Triangulation
Figure 47. Key Executives Interviewed